Invesco Ltd. Raises Holdings in Dynavax Technologies Corporation $DVAX

Key Points

• Invesco Ltd. increased its holdings in Dynavax Technologies by 33.8% in Q1, owning about 2.2 million shares worth $28.6 million.
• Analysts have set a new consensus price target of $24.33 for Dynavax Technologies, with most ratings being "Moderate Buy."
• Dynavax Technologies reported earnings of $0.14 per share for the last quarter, exceeding expectations and achieving revenues of $95.44 million.

Invesco Ltd. grew its position in shares of Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 33.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,207,631 shares of the biopharmaceutical company's stock after purchasing an additional 558,046 shares during the quarter. Invesco Ltd. owned approximately 1.84% of Dynavax Technologies worth $28,633,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. DekaBank Deutsche Girozentrale purchased a new position in shares of Dynavax Technologies during the 1st quarter valued at approximately $30,000. Russell Investments Group Ltd. increased its holdings in shares of Dynavax Technologies by 96.5% during the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 1,169 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Dynavax Technologies during the 4th quarter valued at approximately $35,000. GAMMA Investing LLC increased its holdings in shares of Dynavax Technologies by 88.4% during the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock valued at $100,000 after purchasing an additional 3,627 shares in the last quarter. Finally, Moloney Securities Asset Management LLC purchased a new position in shares of Dynavax Technologies during the 1st quarter valued at approximately $131,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Price Performance

NASDAQ DVAX traded down $0.45 on Friday, hitting $10.50. The company had a trading volume of 3,702,500 shares, compared to its average volume of 1,492,011. The company has a market capitalization of $1.23 billion, a PE ratio of -22.83 and a beta of 1.09. The company's fifty day moving average price is $10.60 and its 200-day moving average price is $11.40. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.65 and a quick ratio of 6.01. Dynavax Technologies Corporation has a 12-month low of $9.22 and a 12-month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.12 by $0.02. The company had revenue of $95.44 million during the quarter, compared to analyst estimates of $87.55 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. As a group, analysts predict that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on DVAX shares. Wall Street Zen raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. JMP Securities reissued a "market outperform" rating and issued a $32.00 price target on shares of Dynavax Technologies in a report on Friday. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $24.33.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.